|

Hemostasis in Liver Cirrhosis and Hepatocellular Cancer

RECRUITINGSponsored by Region Stockholm
Actively Recruiting
SponsorRegion Stockholm
Started2022-12-02
Est. completion2026-12-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06212635

Summary

Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with decompensated liver cirrhosis
* 18 years or older.
* Healthy individuals 18 years or older will serve as controls.

Exclusion Criteria:

* • Extrahepatic malignancy or recurrence of such within the last year.

  * Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion.
  * Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies
  * Previous liver transplantation.
  * Transfusions the last 7 days.
  * Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.

Conditions4

CancerHemostasis in Decompensated Liver CirrhosisInflammation in Decompensated Liver CirrhosisLiver Cancer

Browse More Trials

Cancer trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.